A Pioneer's Overview of Cannabinoids: From Ancient Use to Modern Medicine | Research

The takeaway

Raphael Mechoulam, who first isolated THC, reviewed the field from ancient Assyrian and Chinese use through modern clinical applications in chemotherapy nausea, appetite loss, multiple sclerosis, and neuroprotection.

Read this if you want a sweeping overview of cannabinoid science from the researcher who started the field.

Review by Raphael Mechoulam, who first isolated THC in 1964

What the researchers found

The review traced cannabinoid science from historical use in Assyria and China through to the identification of CB1 and CB2 receptors and the discovery of endogenous cannabinoids. THC had established clinical utility as an anti-vomiting and appetite-enhancing agent. Clinical work in multiple sclerosis was advancing toward potential drug approval.

CBD, described as a non-psychotropic constituent, was showing promise in preclinical studies. Recent animal model work on CBD in rheumatoid arthritis suggested potential clinical applications. A synthetic cannabinoid called HU-211 (Dexanabinol) was in advanced clinical trials as a neuroprotectant for head trauma.

Why it matters

Written by the researcher who first isolated and synthesized THC in 1964, this review carried unique authority. It documented the state of cannabinoid science at a transitional moment when the basic pharmacology was established but clinical applications were still being developed. The mention of CBD for rheumatoid arthritis and synthetic cannabinoids for neuroprotection pointed toward research directions that would expand significantly.

The numbers in context

No specific statistical data were presented in this overview.

How the study worked

This was a narrative review by Raphael Mechoulam, one of the founding researchers in cannabinoid science, covering the historical, pharmacological, and clinical landscape of cannabinoid research. It synthesized findings from preclinical and clinical studies across multiple therapeutic areas.

What this study cannot tell us

As a broad overview by a single researcher, this paper provided perspective rather than systematic analysis. The review covered many therapeutic areas briefly rather than deeply. Some of the promising research directions described did not pan out as anticipated.

How to read the evidence

This is a narrative review by a leading researcher that synthesizes findings across multiple areas, providing moderate-level evidence through expert synthesis.

When this study was published

Published in 2001, this review captures the state of cannabinoid medicine before the major clinical trial era of the 2000s and 2010s.

The bigger picture

Mechoulam's review anticipated several developments that materialized in subsequent years: THC-based medications gained broader approval, CBD became the basis for Epidiolex (approved for epilepsy in 2018), and the endocannabinoid system became a major focus of neuroscience research. However, Dexanabinol (HU-211) did not ultimately achieve regulatory approval for head trauma.

Questions still open

Why did Dexanabinol fail to achieve regulatory approval despite advanced clinical trials? How did Mechoulam's framing of cannabinoid research influence funding and regulatory priorities in subsequent decades?

Common questions

Who is Raphael Mechoulam?

Raphael Mechoulam is an Israeli organic chemist who first isolated and synthesized THC in 1964, and later helped discover the endocannabinoid system. He is widely considered the founding father of cannabinoid research.

What happened with the neuroprotection drug mentioned in this review?

Dexanabinol (HU-211), the synthetic cannabinoid being tested for head trauma neuroprotection, went through clinical trials but did not ultimately achieve regulatory approval, illustrating how promising preclinical results do not always translate to approved treatments.

Read the original research

The cannabinoids: an overview. Therapeutic implications in vomiting and nausea after cancer chemotherapy, in appetite promotion, in multiple sclerosis and in neuroprotection.

Pain research & management, 6(2), 67-73

View on PubMed ↗

Citation

Mechoulam, R; Hanu, L. (2001). The cannabinoids: an overview. Therapeutic implications in vomiting and nausea after cancer chemotherapy, in appetite promotion, in multiple sclerosis and in neuroprotection.. Pain research & management, 6(2), 67-73.